References
- World Health Organization. 10 facts on obesity. [cited 2016 May 13]. Available from: http://www.who.int/features/factfiles/obesity/facts/en/index1.html.
- American Diabetes Association. Standards of medical care in diabetes – 2016. Diabetes Care. 2016;39 (Suppl 1):S1–S112.
- UK Prospective Diabetes Study 7. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism. 1990;39:905–912.
- Goldstein DJ. Beneficial health effects of modest weight loss. In J Obes Relat Metab Disord. 1992;16:397–415.
- Pastors JG, Washaw H, Daly A, et al. The evidence for effectiveness of medical nutrition therapy in diabetes management. Diabetes Care. 2002;25:608–613.
- Aldekhail NM, Logue J, McLoone P, et al. Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2015;16 (12):1071–1080.
- Aprovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guidelines. J Clin Endocrinol Metab. 2015;100 (2):342–362.
- Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8:402–424.
- Genentech USA. Xenical: US prescribing information; 2015 [cited 2016 May 10]. Available from: http://www.gene.com/download/pdf/xenical_prescribing.pdf.
- Derosa G, Maffioli P, Salvadeo SAT, et al. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin Pharmacother. 2010;11(12):1971–1982.
- NPS Medicinewise website. HbA1c unit converter tool for type 1 diabetes. [cited 2016 May 12]. Available from: http://www.nps.org.au/conditions/hormones-metabolism-and-nutritional-problems/diabetes-type-1/for-individuals/tests-and-monitoring/hba1c-unit-converter.
- Blood Sugar Converter. Diabetes.co.uk website. [cited 2016 May 12]. Available from: http://www.diabetes.co.uk/blood-sugar-converter.html.
- GlaxoSmithKline. Alli: US label; 2007. [cited 2016 May 11]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021887lbl.pdf.
- Kim S. Drugs to treat obesity: do they work? Postgrad Med J. 2016;1–6.
- Arena Pharmaceuticals GmbH. Belviq: US prescribing information; 2012 [cited 2016 May 12]. Available from: http://www.belviq.com/documents/Belviq_Prescribing_information.pdf.
- O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obes. 2012;20:1426–1436.
- Nuffer W, Trujillo JM, Megyeri J. A comparison of new pharmacological agents for the treatment of obesity. Ann Pharmacother. 2016;50(5):376–388.
- Teva Pharmaceuticals. ADIPEX-P (phentermine) [package insert]; 2012 [cited 2016 May 1]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf.
- Chen Y. Regulation of food intake and the development of anti-obesity drugs. Drug Discov Ther. 2016 Apr 14;10:62–73. doi:10.5582/ddt.2016.01014.
- Rodríguez JE, Campbell KM. Past, present, and future of pharmacologic therapy in obesity prim care. Prim Care Clin Off Pract. 2016;43:61–67.
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summary. Endocr Pract. 2016;22(1):84–113.
- Vivus Pharmaceuticals. QSYMIA (phentermine/topiramate extended release) [package insert]; 2014 [cited 2016 May 1]. Available from: https://qsymia.com/pdf/prescribing-information.pdf.
- Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–342.
- Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–1352.
- Garvey WT, Ryan DH, Bohannon NJV, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014;37:3309–3316.
- Garvey WT, Ryan DH, Look M, et al. Two year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.
- Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37:912–921.
- Jordan J, Astrup A, Engeli S, et al. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014;32:1178–1188.
- Red Book Online, Micromedex 2.0. Ann Arbor, MI: Truven Health Analytics; [cited 2016 May 1]. Available from: http://www.micromedexsolutions.com.
- European Medicines Agency. Refusal of the marketing authorisation for Qsiva (phentermine /topiramate); 2013 Feb [cited 2016 May 1]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500139215.pdf.
- Qsymia. The European union clinical trials register. [cited 2016 May 1]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=qsymia.
- Takeda Pharmaceuticals America. Contrave [package insert]; 2014 [cited 2016 May 26]. Available from: http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI&cacheRandomizer=4d6db5fc-10bd-40ad-ac1e-7c21e1f3aa8e.
- Hollander P, Gupta A, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–4029.
- Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
- Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obes. 2013;21:935–943.
- Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obes. 2011;19:110–120.
- Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315:990–1004.
- Novo Nordisk. Saxenda® liraglutide (rDNA) injection: US prescribing information; 2014 [cited 2016 May 9]. Available from: http://www.saxenda.com/.
- Knudsen L, Nielsen P, Huusfeldt P, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43:1664–1669.
- Crane J, Barbara M. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2016;7(2):92–107.
- Secher A, Jelsig J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473–4488.
- Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. The SCALE diabetes randomized clinical trial. JAMA. 2015;314 (7):687–699.
- Clinical Trials.gov. A study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects. [cited 2016 May 16]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00112021?term=obesity&type=Intr&age=1&phase=12&rank=40.
- Clinical Trials.gov. A study of safety and efficacy of topiramate in male patients with abdominal obesity. [cited 2016 May 162016]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00231608?term=obesity&type=Intr&age=1&phase=12&rank=22.
- Clinical Trials.gov. The effects of exenatide (Byetta) on energy expenditure and weight loss in nondiabetic obese subject. [cited 2016 May 16]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00856609?term=obesity&type=Intr&age=1&phase=12&rank=103.